Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q1 FY2026 Earnings Presentation
9 slides from Natco Pharma's earnings presentation, Aug 12, 2025
Slide 1: Cover letter to stock exchanges: Q1 FY26 Earnings Presentation
12th August, 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q1 FY 26 Earnings Presentation Please find enclosed herewith the Earnings Prese
Slide 2: NATCO Pharma Limited Earnings Presentation Q1FY26
NATCO Pharma Limited Earnings Presentation Q1FY26
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q1FY26 - Key Business & Consolidated Financial Highlights
Q1FY26 - Key Business & Consolidated Financial Highlights Total Revenue stood for Q1FY26 at INR 6,511atMn| INRPharma 13,906Export Mn | Pharma ExportatFormulations Formulations INR 2,858 Mnat |INR 11,265Formulations Domestic Mn | Domestic Formulations Revenue at INR Revenue at 1,070 Mn 961 Earnings B
Slide 5: Q1FY26 - Quarterly Performance
Q1FY26 - Quarterly Performance Revenue Breakup (%) – Q1FY26 Revenue Division (INR Mn) Q1FY26 Q1FY25 Q4FY25 5 2.5 3.8 7.7 API Revenue 526 392 464 Formulation Formulation – Exports (incl profit share, license income, 81 11,265 12,101 10,525 Export formulation Domestic Formulation export service income
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q1FY26 Q1FY25 Q4FY25 Total Revenue 13,906 14,107 12,873 Total Expenses (before finance cost and depreciation) 7,579 5,578 6,729 Earnings before interest, tax, depreciation and amortization (EBITDA) 6,327 8,529 6,144 EBITDA Margin*
Slide 7: Key product pipeline - USA
Key product pipeline - USA Para IVs in the pipeline, with 28 over 20 FTFs (incl. Sole and 13 Approved (either tentative or fully) Shared) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic segment/ Therapeutic segment/ Brand Molecule Brand
Slide 8: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics Invested US$ 8 million in a biotechnology company Invested US$ 2 million focused on advanced cellular focused on xenotransplantation, by developing safe and engineering methods and gene-therapy-based effective human compati
Slide 9: Earnings Call Details – Q1FY26
Earnings Call Details – Q1FY26 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earnings ca